Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David D Kim
Peter J Neumann

Showing results (51-60 of 436) with videos related to

Pageof 44
Sort By:
The New England Journal of Medicine|October 15, 2010
Legislating against use of cost-effectiveness informationPeter J Neumann, Milton C Weinstein
The New England Journal of Medicine|August 21, 2023
Turning CMS into a Health Technology Assessment OrganizationPeter J Neumann, Sean R Tunis
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|December 11, 2013
Is the US "leading from behind" on health policy?Peter J Neumann, Cayla J Saret
Expert Review of Pharmacoeconomics & Outcomes Research|October 22, 2013
A survey of individuals in US-based pharmaceutical industry HEOR departments: attitudes on policy topicsPeter J Neumann, Cayla J Saret
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|July 18, 2008
Decision analytic models for Alzheimer's disease: state of the art and future directionsJoshua T Cohen, Peter J Neumann
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|August 23, 2015
When Does FDAMA Section 114 Apply? Ten Case StudiesPeter J Neumann, Cayla J Saret
Pharmacoeconomics|October 28, 2006
Economic evaluation in the US: what is the missing link?Peter J Neumann, Sean D Sullivan
American Journal of Preventive Medicine|October 31, 2002
Do HEDIS measures reflect cost-effective practices?Peter J Neumann, Bat Sheva Levine
Medical Decision Making : an International Journal of the Society for Medical Decision Making|May 20, 2020
Analyzing the Cost Effectiveness of Policy Responses for COVID-19: The Importance of Capturing Social ConsequencesDavid Daeho Kim, Peter J Neumann
Fundamental & Clinical Pharmacology|November 30, 2005
Quality-adjusted life years: how useful in medico economic studiesCarmen A Brauer, Peter J Neumann
Pageof 44

Showing results (51-60 of 436) with videos related to

Sort By:
Pageof 44
The New England Journal of Medicine|October 15, 2010
Legislating against use of cost-effectiveness informationPeter J Neumann, Milton C Weinstein
The New England Journal of Medicine|August 21, 2023
Turning CMS into a Health Technology Assessment OrganizationPeter J Neumann, Sean R Tunis
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|December 11, 2013
Is the US "leading from behind" on health policy?Peter J Neumann, Cayla J Saret
Expert Review of Pharmacoeconomics & Outcomes Research|October 22, 2013
A survey of individuals in US-based pharmaceutical industry HEOR departments: attitudes on policy topicsPeter J Neumann, Cayla J Saret
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|July 18, 2008
Decision analytic models for Alzheimer's disease: state of the art and future directionsJoshua T Cohen, Peter J Neumann
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|August 23, 2015
When Does FDAMA Section 114 Apply? Ten Case StudiesPeter J Neumann, Cayla J Saret
Pharmacoeconomics|October 28, 2006
Economic evaluation in the US: what is the missing link?Peter J Neumann, Sean D Sullivan
American Journal of Preventive Medicine|October 31, 2002
Do HEDIS measures reflect cost-effective practices?Peter J Neumann, Bat Sheva Levine
Medical Decision Making : an International Journal of the Society for Medical Decision Making|May 20, 2020
Analyzing the Cost Effectiveness of Policy Responses for COVID-19: The Importance of Capturing Social ConsequencesDavid Daeho Kim, Peter J Neumann
Fundamental & Clinical Pharmacology|November 30, 2005
Quality-adjusted life years: how useful in medico economic studiesCarmen A Brauer, Peter J Neumann
Pageof 44